英可瑞（300713）(300713.SZ)发布2026年度向特定对象发行股票预案，本次发行募集资金总额不超过 3.79亿元(含本数)，在扣除相关发行费用后的募集资金净额将全部用于以下项目：智能高频开关电源系 统生产项目、智能高频开关电源模块生产线自动化及技术升级改造项目、营销网络及信息化建设项目、 智能高频开关电源系统研发中心项目以及补充流动资金。 ...

长江产业集团将现金全额认购，所购股份36个月内不得转让。资金主要用于偿还借款和补充流动资金， 以优化资本结构，降低资产负债率。截至2025年9月30日，公司资产负债率为62.67%，较高的负债率增 加了债务融资成本。此次定增有助于缓解资金压力，增强抗风险能力与盈利能力。 广济药业主营维生 素B2、B6及医药制剂产品，是全球主要的维生素B2供应商之一。近年来，受市场竞争加剧影响，主要 产品销售价格长期低位，导致业绩持续亏损。财报显示，2023年至2025年，公司净利润连续三年亏损， 且亏损金额持续增长。此外，产线开工率不足、产品市场价格下行等因素也对公司业绩造成不利影响。 据经济观察报-经济观察网 2月11日，广济药业（000952.SZ）公告拟向控股股东长江产业投资集团有限 公司定增募资。 本次发行股票数量不超过94,936,708股，价格为6.32元/股，募集资金总额不超过6亿 元。 市场研究机构预计，2026年开始维生素B2或进入温和增长期。对于广济药业而言，能否依靠控股股东 的驰援扛过周期底部，仍待进一步观察。 ...

Core Viewpoint - Guangji Pharmaceutical (000952.SZ) has proposed a private placement plan to raise up to 600 million yuan, seeking support from its controlling shareholder, Changjiang Industrial Investment Group, amid a projected loss of 399 million to 518 million yuan for 2025 [1][5]. Group 1: Private Placement Details - The private placement will involve a cash subscription by Changjiang Industrial Group, which holds 25.26% of Guangji Pharmaceutical's shares [2]. - The issuance price is set at 6.32 yuan per share, not lower than 80% of the average trading price over the previous 20 trading days [2]. - The number of shares to be issued will not exceed 94,936,708, representing up to 30% of the company's total shares prior to the issuance [2]. Group 2: Company Background and Market Context - Guangji Pharmaceutical specializes in Vitamin B2, B6, and pharmaceutical formulations, being a major global supplier of Vitamin B2, with applications in pharmaceuticals, feed additives, and food additives [3]. - The company has faced continuous net profit losses for three years, with losses increasing from 140 million yuan in 2023 to an expected 399 million to 518 million yuan in 2025, primarily due to low market prices for Vitamin B2 [5][6]. - The demand for vitamins is expected to rise due to improving living standards and health awareness, supported by government policies promoting high-quality vitamin production [3]. Group 3: Financial Health and Future Outlook - As of September 30, 2025, the company's debt-to-asset ratio was 62.67%, indicating high debt financing costs [4]. - The company has been experiencing operational losses due to low production line utilization and declining product prices, leading to asset impairment [6][7]. - Market analysts predict a mild growth phase for Vitamin B2 starting in 2026, with potential stabilization of prices and improved production efficiency due to technological upgrades [7].

Core Viewpoint - Foresight Technology (301529.SZ) announced a plan to issue A-shares to specific investors, aiming to raise up to RMB 960 million for various projects, including the construction of manufacturing bases and digital upgrades of core production equipment [1][3]. Group 1: Fundraising Details - The total amount to be raised is capped at RMB 96,000,000, which will be allocated to four main projects: Wuhu automotive interior manufacturing base (RMB 32,000,000), Thailand production base (RMB 37,000,000), digital upgrade of core production equipment (RMB 9,000,000), and working capital (RMB 18,000,000) [1][3]. - The shares will be issued as RMB ordinary shares (A-shares) with a par value of RMB 1.00 each, and the issuance will be limited to no more than 35 specific investors [4][5]. Group 2: Issuance Conditions - The pricing for the shares will be based on 80% of the average trading price over the 20 trading days prior to the issuance date [4]. - The maximum number of shares to be issued will not exceed 30% of the company's total shares before the issuance, amounting to 25,451,163 shares [4][5]. Group 3: Shareholder Control - After the issuance, the controlling shareholder, Lu Wenbo, will still maintain control with a reduced stake of 28.75%, ensuring no change in the company's actual control [5]. - The shares acquired through this issuance will have a lock-up period of six months post-issuance, with specific regulations governing any subsequent sales [5]. Group 4: Recent Company Performance - Foresight Technology was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on September 11, 2023, with an initial issuance of 21,209,303 shares at a price of RMB 36.60 per share [6]. - The company raised a total of RMB 776.26 million from its previous issuance, exceeding its initial target by RMB 228.23 million [7].

2026年2月5日，公司发布了2025年度以简易程序向特定对象发行股票的预案（二次修订稿），拟募集资 金1.59亿元用于陆芝葆化药生产车间与智能综合仓库项目建设。发行价格为8.45元/股，需经深圳证券交 易所审核及中国证监会注册后方可实施。 业绩经营情况 经济观察网 北陆药业（300016）发布定增预案，拟募资1.59亿元用于项目建设，同时公司预计2025年净 利润同比大幅增长537.28%至852.26%。此外，公司正积极拓展海外市场并推进产能扩建。 定增股票 2026年1月29日，公司预计2025年全年归属于上市公司股东的净利润为8700万元至1.3亿元，同比增长 537.28%至852.26%。正式年报尚未发布，最终数据以审计结果为准。 产能扩充 根据2026年1月22日的机构调研信息，公司正积极拓展海外市场，对比剂生产线已通过欧盟及巴西认 证，并推进海昌药业原料药产能扩建、沧州三期原料生产项目等，以支撑未来业务增长。 以上内容基于公开资料整理，不构成投资建议。 ...

广济药业（000952）(000952.SZ)发布2026年向特定对象发行A股股票预案，本次向特定对象发行股票的 发行对象为公司控股股东长江产业集团，发行对象符合法律、法规的规定。本次发行的股票全部采用现 金方式认购。预计募集资金总额不超过6亿元(含本数)，扣除发行费用后用于偿还借款和补充流动资 金。 ...

Core Viewpoint - Longi Technology (300835.SZ) plans to raise a total of up to 760 million yuan through a private placement of shares, with the funds allocated for various projects including the second phase of its Vietnam project, chip inductor manufacturing, working capital, and repayment of bank loans [1] Group 1 - The company aims to raise funds not exceeding 760 million yuan [1] - The raised funds will be used for the second phase of the Vietnam project [1] - The funds will also support the chip inductor manufacturing project [1] Group 2 - Additional allocations include replenishing working capital [1] - Part of the funds will be used to repay bank loans [1]

Group 1 - The company plans to issue up to 25.45 million A-shares to no more than 35 specific investors, aiming to raise a total of no more than 960 million yuan [1] - The net proceeds from the fundraising, after deducting issuance costs, will be used for the construction of the Wuhu automotive interior manufacturing base, the Thailand production base, the digital iteration and upgrade of core production equipment, and to supplement working capital [1]

格隆汇2月11日丨紫光股份(000938.SZ)公布，拟向特定对象发行A股股票募集资金总额不超过55.7亿元 （含本数），扣除发行费用后的净额投资于收购新华三6.98%股权、研发设备购置项目、偿还银行贷 款。 如何抓住黄金波段机会？聪明钱的选择，黄金+股票一键搞定>> ...

Group 1 - The core point of the article is that Xinhan New Materials (301076.SZ) plans to issue A-shares to specific investors, aiming to raise no more than 1 billion yuan [1] Group 2 - The net proceeds from the fundraising, after deducting issuance costs, will be invested in several projects, including the construction of a facility with an annual production capacity of 8,100 tons of high-performance resins and composite materials [1] - Another project involves the annual production of 5,000 tons of monomers and their supporting engineering projects [1] - Additionally, the funds will be allocated to the establishment of an innovation center for high-performance composite materials [1]